Insulin down-regulates specific activity of ATP-binding cassette transporter A1 for high density lipoprotein biogenesis through its specific phosphorylation

Atherosclerosis

Volumn 216, Issue 2, 2011, Pages 334-341

  Nonomura, Kazuhiko ^a   Arai, Yoshie ^b   Mitani, Hironobu ^b   Abe Dohmae, Sumiko ^a   Yokoyama, Shinji ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NOVARTIS PHARMA K K   (Japan)

Author keywords

ABCA1; Atherosclerosis; Cholesterol; HDL; Hyperinsulinism; Phosphorylation

Indexed keywords

ABC TRANSPORTER A1; HIGH DENSITY LIPOPROTEIN; INSULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BIOGENESIS; BIOSYNTHESIS; CELL CULTURE; DOWN REGULATION; HUMAN; HUMAN CELL; HYPERINSULINEMIA; INSULIN RESISTANCE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT;

ANIMALS; ATHEROSCLEROSIS; ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; DISEASE MODELS, ANIMAL; DOWN-REGULATION; HUMANS; HYPERINSULINISM; INSULIN; INSULIN RESISTANCE; KINETICS; LIPIDS; LIPOPROTEINS, HDL; MALE; PHOSPHORYLATION; RATS; RECEPTOR, INSULIN;

EID: 79957999890     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.02.021     Document Type: Article

References (30)

1. Hunt K.J., Resendez R.G., Williams K., Haffner S.M., Stern M.P. National education program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascualr mortality in the San Antonio Heart Study. Circulation 2004, 110:1251-1257.
2. Semenkovich C.F. Insulin resistance and atherosclerosis. J Clin Invest 2006, 116:1813-1822.
3. Karhapaa P., Malkki M., Laakso M. Isolated low HDL cholesterol: an insulin-resistant state. Diabetes 1994, 43:411-417.
4. Zavaroni I., Bonini L., Fantuzzi M., Dall'Aglio E., Passeri M., Reaven G.M. Hyperinsulinaemia, obesity, and syndrome X. J Int Med 1994, 235:51-56.
5. Bonora E., Capaldo B., Perin P.C., Del Prato S., De Mattia G., Frittitta L., et al. G.o.I.S.o.I.R (GISIR), Hyperinsulinemia and insulin resistance are independently associated with plasma lipids, uric acid and blood pressure in non-diabetic subjects. The GISIR database. Nutr Met Cardiovasc Dis 2008, 18:624-631.
6. Rashid S., Watanabe T., Sakaue T., Lewis G.F. Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity. Clin Biochem 2003, 36:421-429.
7. Miller A.W., Katakam P.V., Ujhelyi M.R. Impaired endothelium-mediated relaxation in coronary arteries from insulin-resistant rats. J Vasc Res 1999, 36:385-392.
8. Hogarth C.A., Roy A., Ebert D.L. Genomic evidence for the absence of a functional cholesteryl ester transfer protein gene in mice and rats. Comp Biochem Physiol: B Biochem Mol Biol 2003, 135:219-229.
9. Yokoyama S. Assembly of high-density lipoprotein. Arterioscler Thromb Vasc Biol 2006, 26:20-27.
10. Attie A.D. ABCA1: at the nexus of cholesterol, HDL and atherosclerosis. Trends Biochem Sci 2007, 32:172-179.
11. Timmins J.M., Lee J.Y., Boudyguina E., Kluckman K.D., Brunham L.R., Mulya A., et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 2005, 115:1333-1342.
12. Brunham L.R., Kruit J.K., Iqbal J., Fievet C., Timmins J.M., Pape T.D., et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006, 116:1052-1062.
13. Biddinger S.B., Hernandez-Ono A., Rask-Madsen C., Haas J.T., Aleman J.O., Suzuki R., et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 2008, 7:125-134.
14. Venkateswaran A., Laffitte B.A., Joseph S.B., Mak P.A., Wilpitz D.C., Edwards P.A., et al. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci USA 2000, 97:12097-12102.
15. Tamehiro N., Shigemoto-Mogami Y., Kakeya T., Okuhira K., Suzuki K., Sato R., et al. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 2007, 282:21090-21099.
16. Arakawa R., Yokoyama S. Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation. J Biol Chem 2002, 277:22426-22429.
17. Lu R., Arakawa R., Ito-Osumi C., Iwamoto N., Yokoyama S. ApoA-I facilitates ABCA1 recycle/accumulation to cell surface by inhibiting its intracellular degradation and increases HDL generation. Arterioscler Thromb Vasc Biol 2008, 28:1820-1824.
18. Yokoyama S., Tajima S., Yamamoto A. The process of dissolving apolipoprotein A-I in an aqueous buffer. J Biochem 1982, 91:1267-1272.
19. Hu W., Abe-Dohmae S., Tsujita M., Iwamoto N., Ogikubo O., Otsuka T., et al. Biogenesis of HDL by SAA is dependent on ABCA1 in the liver in vivo. J Lipid Res 2008, 49:386-393.
20. Kojima K., Abe-Dohmae S., Arakawa R., Murakami I., Suzumori K., Yokoyama S. Progesterone inhibits apolipoprotein-mediated cellular lipid release: a putative mechanism for the decrease of high-density lipoprotein. Biochim Biophys Acta 2001, 1532:173-184.
21. Abe-Dohmae S., Ikeda Y., Matsuo M., Hayashi M., Okuhira K., Ueda K., et al. Human ABCA7 supports apolipoprotein-mediated release of cellular cholesterol and phospholipid to generate high density lipoprotein. J Biol Chem 2004, 279:604-611.
22. Iwamoto N., Lu R., Tanaka N., Abe-Dohmae S., Yokoyama S. Calmodulin interacts with ATP binding cassete transporter A1 to protect from calpain-mediated degradation and upregulates high-density lipoprotein generation. Arterioscler Thromb Vasc Biol 2010, 30:1446-1452.
23. Abe-Dohmae S., Suzuki S., Wada Y., Aburatani H., Vance D.E., Yokoyama S. Characterization of apolipoprotein-mediated HDL generation induced by cAMP in a murine macrophage cell line. Biochemistry 2000, 39:1092-11099.
24. Tsujita M., Wu C.A., Abe-Dohmae S., Usui S., Okazaki M., Yokoyama S. On the hepatic mechanism of HDL assembly by the ABCA1/apoA-I pathway. J Lipid Res 2005, 46:154-162.
25. Hossain M.A., Tsujita M., Gonzalez F.J., Yokoyama S. Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes. J Cardiovasc Pharmacol 2008, 51:258-266.
26. White M.F., Takayama S., Kahn C.R. Differences in the sites of phosphorylation of the insulin receptor in vivo and in vitro. J Biol Chem 1985, 260:9470-9478.
27. Yamauchi Y., Hayashi M., Abe-Dohmae S., Yokoyama S. Apolipoprotein A-I activates protein kinase alpha signaling to phosphorylate and stabilize ATP binding cassette transporter A1 for the high density lipoprotein assembly. J Biol Chem 2003, 278:47890-47897.
28. Saltiel A.R., Kahn C.R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001, 414:799-806.
29. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin receptor substrate-1 and increased expression of p85 alpha: the two sides of a coin. Diabetes 2006, 55:2392-2397.
30. Tanti J.F., Jager J. Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation. Curr Opin Pharmacol 2009, 9:753-762.